ICMR published “National Guidelines for Gene Therapy Product Development and Clinical Trails”. Which of the following statements are correct about Gene Therapy Product (GTP)? 1. It is defined as any…

Question

ICMR published “National Guidelines for Gene Therapy Product Development and Clinical Trails”. Which of the following statements are correct about Gene Therapy Product (GTP)? 1. It is defined as any biological entity, having the required gene, that could introduce modifications in the genome for therapeutic benefit. 2. GTPs work by repairing, replacing or deactivating dysfunctional disease-causing genes to restore normal function. 3. As per the New Drugs and Clinical Trial Rules (2019), the GTPs falls under ‘new drug’ and shall always be deemed as ‘new drug’. 4. Thalassemia, Gaucher՚s disease, Sickle cell anaemia and Haemophilia fall under the genetically inherited disease category. Select the correct answer using the code given below:

PYQPulse · Accepted Answer

1,2, 3 and 4

PYQPulse · Answer

Explanation: All four are correct: GTPs are gene-bearing biological entities that repair/replace/deactivate faulty genes, are deemed 'new drugs' under the 2019 Rules, and target inherited disorders like thalassemia and haemophilia.

Answer: D. 1,2, 3 and 4

Explanation

Answer: D. 1,2, 3 and 4

Explanation